Newcourt Acquisition Corp. (NCAC) Closes Psyence Deal
by Marlena Haddad on 2024-01-25 at 6:14pm

Newcourt (NASDAQ:NCAC) has closed its combination with psychedelic medicine company Psyence (CSE:PSYG) and will begin trading on The Nasdaq under the new ticker symbol ticker symbol “PBM” on January 26.

Shareholders previously approved the combination during a special meeting held on January 18.

In connection with last week’s vote, shareholders opted to redeem 929,727 shares at a redemption price of approximately $11.51 per share, removing about $10.7 million from Newcourt’s trust and leaving it with 183,294 public shares outstanding and about $2.1 million in trust.

In connection with the combination, Psyence Biomed entered into a securities purchase agreement under which it will raise up to $10 million in funding through the issuance of up to four senior secured convertible notes with a US-based investment firm. The combined company intends to use the note financing to further its clinical trials conducted in Australia.

Psyence Biomed has partnered with the Australian-based research organization iNGENu to conduct its clinical trial in palliative care. Upon successful completion of the study, the combined company plans to conduct a multinational Phase III study.

The SPAC announced its deal with Psyence in January 2023. The Canada-listed company is developing psychedelic drug candidates to potentially treat patients in palliative care and those with severe psychological conditions.

Psyence Biomedical plans to use the funds from the deal to expedite its clinical trials and expand its market presence.


ADVISORS

  • Bayline Capital Partners Inc. is acting as capital markets advisor to Psyence.
  • WeirFoulds LLP is acting as Canadian legal advisor to Psyence.
  • Morgan, Lewis & Bockius LLP is acting as U.S. legal advisor to Psyence.
  • McDermott Will & Emery LLP is acting as U.S. legal advisor to Newcourt.
Recent Posts
by Nicholas Alan Clayton on 2024-05-02 at 3:03pm

Online casino and sports company Rush Street (NYSE:RSI) is up +18.4% in trading today on the back of a solid first quarter earnings release, bringing the company’s stock to its highest price since the second half of 2022 (currently $7.60). This makes it the latest in a line of 2020 and 2021 de-SPACs that have...

by Nicholas Alan Clayton on 2024-05-02 at 10:56am

Mountain Crest V (NASDAQ:MCAG) broke a long dealmaking silence by SPACs this morning, albeit with a non-binding agreement to combine with Seoul-based diagnostic biotech firm CUBEBIO. The term sheet would give the company a $620 million pre-transaction equity value and help accelerate the rollout of CUBEBIO’s CEED-NOVUS cancer screening kit products. The company signed an...

by Nicholas Alan Clayton on 2024-05-02 at 8:45am

Churchill Capital Corp IX (NASDAQ:CCIXU) announced the pricing of its $250 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “CCIXU”, Thursday, May 2, 2024. The new SPAC will conduct a broad search and has not limited itself to any particular sector or focus, but it plans to...

by Nicholas Alan Clayton on 2024-05-02 at 7:40am

At the SPAC of Dawn Layoffs in the tech sector ticked down in March to 7,322, making it the most merciful period of 2024 so far for tech workers after back-to-back months that saw nearly 35,000 let go in total, according to Layoffs.fyi. The dip could be an indication that the contraction in tech funding...

by Nicholas Alan Clayton on 2024-05-02 at 7:00am

Cruise operator Viking Holdings (NYSE:VIK) put to sea with its traditional IPO yesterday and immediately showed that the public market winds could be favorable for more SPAC hospitality deals. Viking debuted near the top of its $21 to $25 range at $24, and immediately cruised up about +8.7% further to a day one close at...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved